The new era of residual risk reductionNov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands
Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.
Video navigation menu
- From group treatment to individual approach 00:30
- Further LDL-c lowering beyond guideline targets 01:27
- Reduction of inflammatory residual risk: CANTOS trial 02:57
- The role of arterial coagulation in the pathogenesis of atherosclerotic events: COMPASS trial 04:28
- Choices in high CV-risk patients: personalized therapy 05:04
- From block buster therapies to tailored therapy 07:14
This educational video is part of a series of Inflammation videos that are aimed to provide guidance and perspectives on the implications of addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Prof. Erik Stroes is Internist Vascular Medicine at the Dept. of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Funding to produce this educational video was provided by an unrestricted educational grant from Novartis.